Cyclosporine Treatment For Sun Sensitive Conditions Research

Research articles regarding cyclosporine treatment  for people with sun sensitivity. For more information, visit www.pubmed.com to continue searching.  At pubmed, enter your search criteria. Once you have results, choose the Display option "abstracts". Once you find an article you like, click "Related Articles" to find similar articles.

Medline Plus gives a good description of cylcosporine. 
 http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202176.html 

Chronic actinic dermatitis treated with cyclosporine-A.

Stinco G, Codutti R, Frattasio A, De Francesco V, Patrone P., Eur J Dermatol. 2002 Sep-Oct;12(5):455-7. 
Institute of Dermatology, University of Udine, Via Battifero 1, 33013 Germona del Friuli (UD), Italy. dermatologia-univ-ud@libero.it

Chronic actinic dermatitis (CAD) groups together all chronic photodermatosis with light photosensitivity. We report the case of a 69-year-old man who, for over one year, had presented a reddish-brown erythema and shedding, with thickened and hypo-elastic skin on the face, scalp, neck and on the back of the hands and forearms. Patch tests were positive to isoeugenolo 1% and photo-patch tests showed a positivity to phenotiazine 2%. After a short and ineffective treatment with beta-carotene and photo-protectors, the clinical picture was resolved with the administration of oral steroids but with a relapse of the dermatitis once the dosage was lowered. We therefore started treatment with cyclosporine-A (4.5 mg/kg/die), which resulted in a rapid improvement of the clinical picture, but with a reappearance of the manifestations when the dosage was lowered. The treatment was resumed and we observed that the dose of 1.5/mg/kg/die resulted morbus-static. The patient is still being treated with this drug at this dosage. The result is that the disease is under control and no side effects are present. As we consider CAD an invalidating disease it seems to us that Cy-A could be taken into consideration as an alternative to traditional treatments.

PMID: 12370134 [PubMed - indexed for MEDLINE]

Polymorphic light eruption treated with cyclosporin.
Shipley DR, Hewitt JB., Br J Dermatol. 2001 Feb;144(2):446-7.

PMID: 11251609 [PubMed - indexed for MEDLINE]

Severe chronic actinic dermatitis treated with cyclosporine: 2 cases
[Article in French]
Paquet P, Pierard GE., Ann Dermatol Venereol. 2001 Jan;128(1):42-5.
Service de Dermatopathologie, CHU du Sart Tilman, B-4000 Liege, Belgique.

INTRODUCTION: The treatment of the severe forms of photodermatoses often requires potent systemic immunosuppressive drugs. We report two patients suffering from severe photodermatitis successfully treated with oral cyclosporine. CASES REPORT: A 58-year-old man developed severe pruritic eczematous reactions for several years on light-exposed and light-protected skin following each sun exposure. A 66-year-old man showed similar lesions restricted to the head and neck. The clinical presentation and evolution as well as histologic, immunohistologic, allergologic and photobiologic assessments suggested the diagnosis of actinic reticuloid and persistent light reactivity, respectively. The lesions of both patients did not respond to a high dose regimen of systemic corticosteroids (methylprednisolone 1 mg/kg/day) for several weeks. The severity of cutaneous lesions and pruritus required another potent immunosuppressive treatment. Oral cyclosporine at the maximum daily dose of 4 mg/kg was given for three months. A rapid improvement of the pruritus and skin lesions occurred in the two patients, without significant side-effect. The first patient experienced recurrent lesions after termination of cyclosporine treatment during summer time. The other patient did not develop new skin eruption for 3 years after stopping the initial treatment with cyclosporine. DISCUSSION: Low-dose oral cyclosporine is a quick-acting and well tolerated symptomatic treatment of severe photodermatoses resistant to other systemic immunosuppressive drugs. However, therapeutic results do not consistently exhibit long-standing remanent effect.
PMID: 11226900 [PubMed - indexed for MEDLINE]

Use of topical cyclosporin for conjunctival manifestations of actinic prurigo.
McCoombes JA, Hirst LW, Green WR., Am J Ophthalmol. 2000 Dec;130(6):830-1.
Division of Ophthalmology, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.

PURPOSE: To report the successful treatment of conjunctival manifestations of actinic prurigo with topical cyclosporin. METHODS: A 12-year-old female with extensive limbal lesions and chronic conjunctivitis secondary to actinic prurigo was treated with topical cyclosporin, and a rapid clinical response was observed. RESULTS: The patient had the limbal lesions surgically excised. The lesions completely recurred over the first 2 postoperative months. Treatment with topical steroids and vitamin A ointment was unsuccessful. The patient was then treated with cyclosporine 2% drops and a dramatic improvement occurred. Over a 3-month period, the lesions completely resolved. CONCLUSION: Cyclosporine eyedrops may be an effective treatment for the conjunctival manifestations of actinic prurigo.
PMID: 11124306 [PubMed - indexed for MEDLINE]

Long-term follow-up of eczema patients treated with cyclosporine.
Granlund H, Erkko P, Reitamo S., Acta Derm Venereol. 1998 Jan;78(1):40-3.
Department of Dermatology, Helsinki University Central Hospital, Finland.

Cyclosporine is efficacious in short-term treatment of various eczematous disorders. In a follow-up study we have evaluated the long-term efficacy of cyclosporine in 75 patients, who in previous studies had been treated with cyclosporine for chronic actinic dermatitis (6 patients), atopic dermatitis (42 patients) and chronic hand eczema (27 patients), 4, 2 and 1 year after the initial treatment, respectively. Three out of 6 patients with chronic actinic dermatitis showed long-term efficacy. Two years after the initial treatment with cyclosporine (5 mg/kg/day for 1-2 treatment periods of 6 weeks) for atopic dermatitis the mean disease activity was significantly lower compared to baseline (58% decrease), and compared to the time of treatment stop no significant change had occurred. Of 37 evaluable patients 35 were still in remission. One year after the initial treatment with cyclosporine (3 mg/kg/day for 6 weeks) for chronic hand eczema the mean disease activity was significantly lower than at baseline (54% decrease), and compared to the time of treatment stop no significant change had occurred. Of 27 evaluable patients 21 patients were still in remission. The study suggests that long-term remissions are possible in eczematous diseases treated with cyclosporine, even for a relatively short treatment period. It must be stressed, however, that we did not have control groups for any of the studied patient groups.

PMID: 9498025 [PubMed - indexed for MEDLINE]

Cyclosporin A therapy for severe solar urticaria.

Edstrom DW, Ros AM., Photodermatol Photoimmunol Photomed. 1997 Feb-Apr;13(1-2):61-3.

Department of Dermatology, Karolinska Hospital, Stockholm, Sweden.

Solar urticaria is characterized by itching weals that occur a few minutes after exposure to visible or ultraviolet light. The symptoms may sometimes restrict normal daily life. Treatment is difficult in more severe cases. We describe one patient with solar urticaria who was successfully treated with cyclosporin A. The patient had first been treated with antihistamine, PUVA and chloroquine phosphate without effect. Cyclosporin was given in a dose of 4.5 mg/kg body weight/day. Phototesting before, during and after treatment showed a decreased light sensitivity to UVA, UVB and visible light during cyclosporin treatment compared with phototesting before therapy. The patient could be out in the sun for at least 1 h with minimal urticaria during cyclosporin therapy compared with only a few minutes previously. However, 1-2 weeks after cyclosporin therapy was discontinued, skin symptoms returned. Cyclosporin therapy is a possible treatment in severe cases of solar urticaria where other treatments have failed, especially in countries where treatment is necessary only for a few months during summer.

PMID: 9361130 [PubMed - indexed for MEDLINE]

Successful treatment of musk ketone-induced chronic actinic dermatitis with cyclosporine and PUVA.

Gardeazabal J, Arregui MA, Gil N, Landa N, Raton JA, Diaz-Perez JL., J Am Acad Dermatol. 1992 Nov;27(5 Pt 2):838-42.

Department of Dermatology, Hospital de Cruces, University of the Basque Country, Bilbao, Vizcaya, Spain.

We describe a patient with chronic actinic dermatitis whose photopatch tests revealed reactions to musk ketone and musk ambrette, both of which were found in his aftershave lotion. Minimal erythema doses of UVA and UVB were decreased. After initial unsuccessful treatment with PUVA therapy the patient was successfully treated with a combination of cyclosporine and PUVA.

PMID: 1469140 [PubMed - indexed for MEDLINE]